Haemonetics Corp. (HAE) has issued an announcement.
Haemonetics Corporation revamped its financing structure by entering into a new credit agreement that refines the terms of its 2022 agreement with JPMorgan Chase Bank. The updated deal secures a $250 million term loan and boosts its revolving credit facility to $750 million. This financial maneuver is set to extend the company’s credit maturity to April 2029, offering a flexible interest rate tied to the SOFR Rate plus an additional percentage contingent on the company’s leverage ratio. Additionally, the agreement outlines financial covenants and allows for certain debt exclusions, providing Haemonetics with strategic leverage for future growth and investments.
For an in-depth examination of HAE stock, go to TipRanks’ Stock Analysis page.
